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Ling Zhi-8: A Fungal Protein With Immunomodulatory Effects
L.G. van der Hem, J.A. van der Vliet, K. Kino, A.J. Hoitsma, and W.J.M. Tax
ING ZHI-8 (LZ-8) is a protein from the mycclial
extracts of Ganodcrma lucidiun and has immuno­
modulatory capacities.1 Formerly it was reported to be 
mitogenic toward mouse splenocytes and suppressive in 
vivo by reducing HBsAg-specific antibody production2 and 
by preventing the incidence of diabetes in NOD mice. To 
specify possible clinical use of LZ-8, the mitogcnic effects of 
LZ-8 were tested in the presence of human mononuclear 
cells (MNC) and T lymphocytes, as well as suppressive 
capacities of LZ-8 in vitro in an MLC with MNC or T 
lymphocytes and Epstein-Barr Virus-transformed (EBV) 
B cells. The immunosuppressive effects of LZ-8 were also 
investigated in a model of allogeneic mouse skin transplan­
tation and in a model of allografted rat pancreatic islets.
MATERIALS AND METHODS 
Mitogenic Activity of LZ-8
Human MNC or purified T cells were incubated with 3 LZ-8 
concentrations (0.1, 1, and 10 ju.g/mL) for 3, 4, 5, 6, and 7 days.
Immunosuppressive Activity of LZ-8 In Vitro
Human T cells were incubated with irradiated allogeneic EBV-B 
cells and LZ-8 in three concentrations (0.1, i, and 10 /^ g/rnL) for 6 
days.
Mouse Skin Transplantation
B10.D2 mice (H-I*) served as skin donors and C57B110 mice 
(H-2b) as recipients. Full-thickness skin flaps were attached to the 
flank of recipients after removal of a corresponding skin area. 
Rejection occurred on the day of complete necrosis of the trans­
planted skin. Group 1 (controls, n ~ 12) received an injection of 
saline, twice per week; group 2 (n = 11) received 15 mg/kg LZ-8, 
twice per week; and group 3 (n = 12) received 7.5 mg/kg LZ-8 four 
times per week.
Rat Pancreatic Islet Transplantation
Lewis rats (RT-Î1) were the donors of pancreatic islets and diabetic 
(streptozotocin IV) F344 rats (RT-llv) were the recipients of two 
donor islet grafts, Pancreatic islets were obtained after intraductal 
distension with collagenase, stationary digestion, filtration, and 
density gradient centrifugation, as published earlier.4 Rejection 
occurred on the first of 3 days with blood glucose >11 mmol/L. 
Group A (controls, n = 9) received no postoperative immunosup­
pression, Group B (n = 6) received an injection of 15 mg/kg LZ-8 
twice per week posttransplant and group C (n = 6) 5 mg/kg LZ-8 
daily. Group D (n = 6) had continuous LZ-8 injection by an 
osmotic minipump in a concentration of 5 mg/mL with a volume of
2 mL and an operational period of 7 days.
RESULTS
Mitogenic Activity of LZ-8
A strong mitogenic response was observed in all incubations 
of LZ-8 with human MNC, Peak activity was measured 
after 3 days of incubation with 1 /xg/mL LZ-8. The stimu­
latory activity decreased rapidly for all LZ-8 concentrations 
after 4 days. In the absence of monocytes, there was hardly 
any LZ-8-induced stimulation of human T cells.
Immunosuppressive Activity of LZ-8 In Vitro
The mitogenic response of LZ-8 on human MNC, contain­
ing monocytes, overruled the possible immunosuppressive 
effects of LZ-8 in a MLC. In a modified MLC with T cells 
and allogeneic EBV-B cells, significant suppression of 
T-cell activation was achieved by LZ-8. Addition of 0.1 
¡ig/mL LZ-8 resulted in 42% inhibition, 1 ¡ig/mL in 53%, 
and 10 jug/mL in 66% inhibition.
*
Mouse Skin Transplantation
Administration of LZ-8 led to increased mean survival 
times (MST) of allogeneic mouse skin. MST ± SD were, 
respectively: 10.2 ± 1.1 days in group 1 (controls), 11.5 ± 
1.8 days in group 2; and 13.3 ± 2.9 days in group 3 (group
3 vs 1 :P <  .01).
Rat Pancreatic Islet Transplantation
Treatment with LZ-8 resulted in markedly prolonged graft 
survival. Group A (controls) rejected their islet grafts after 
4.7 ± 0.15 days. MST ± SD of transplanted islets in group 
B was 9.7 ± 0.8 days and in groups C and D 11.0 ± 0.7 days 
and 12.5 ±1.2 days, respectively (groups B, C, D vs A: P < 
.01; and B vs D: P < .05).
DISCUSSION
LZ-8 proves to have paradoxical immunomodulating ef­
fects. In the presence of monocytes, a strong mitogenic 
response on human MNC by LZ-8 was obtained. Evident
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immunosuppression by LZ-8 was demonstrated on the 
proliferative response of T cells with EBV-B cells in the 
absence of monocytes. Also, in both tested in vivo alloge­
neic transplantation models, significant improval of MST 
was achieved by LZ-8 in comparison with controls. No toxic 
side effects of LZ-8 could be discerned in these studies. 
Future studies should address exact modes of action of 
LZ-8.
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